News & Updates

Show Multimedia Only

US FDA greenlights first pill for postpartum depression

31 Aug 2023 by

The US Food and Drug Administration (FDA) has approved the first oral medication for postpartum depression in adults, giving clinicians a new therapeutic option for this debilitating condition.

US FDA greenlights first pill for postpartum depression

31 Aug 2023

General anaesthesia and oxytocin significantly associated with PPH in twin pregnancies

31 Aug 2023 by

A retrospective cohort study of twin pregnancies in Hong Kong has identified general anaesthesia (GA) and use of oxytocin as significant risk factors for all postpartum haemorrhage (PPH; ≥500 mL). The study also shows that GA, in vitro fertilization (IVF), antepartum haemorrhage, placental abruption, and placenta praevia (PP) are significantly associated with major PPH (>1,000 mL), while IVF, PP, and obesity are significant risk factors for severe PPH (>1,500 mL).

General anaesthesia and oxytocin significantly associated with PPH in twin pregnancies

31 Aug 2023

Niraparib maintenance prolongs PFS in advanced ovarian cancer

29 Aug 2023 by

Maintenance therapy with niraparib significantly extends progression-free survival (PFS) compared with placebo in patients with newly diagnosed advanced ovarian cancer who responded to treatment with first-line platinum-based chemotherapy, according to the PRIME* trial.

Niraparib maintenance prolongs PFS in advanced ovarian cancer

29 Aug 2023

Magnesium sulfate for women at risk of preterm birth does not reduce cerebral palsy risk

19 Aug 2023

For pregnant women at risk of delivering preterm, intravenous administration of magnesium sulfate prior to preterm birth at 30–34 week of gestation does not appear to minimize the chances of child survival free of cerebral palsy at 2 years, as shown in a study.

Magnesium sulfate for women at risk of preterm birth does not reduce cerebral palsy risk

19 Aug 2023

OGTT-based model predicts GDM in pregnant women

18 Aug 2023

The current diagnostic criteria being used to predict gestational diabetes mellitus (GDM) is not fully reliable, but adding oral glucose tolerance test (OGTT) to the model may improve early prediction of GDM, according to a study.

OGTT-based model predicts GDM in pregnant women

18 Aug 2023

Oral contraceptive use not linked to CVD, all-cause death in women

18 Aug 2023

Women who use oral contraceptives do not have an excess risk of cardiovascular disease (CVD) events and all-cause death, with the contraceptives potentially conferring benefits to those who have used them for longer, according to a study.

Oral contraceptive use not linked to CVD, all-cause death in women

18 Aug 2023

Relugolix combo reduces dysmenorrhea, NMPP in premenopausal women

17 Aug 2023 by

The use of relugolix 40 mg in combination with oestradiol 1 mg and norethisterone acetate 0.5 mg (relugolix combination therapy [relugolix-CT]) significantly reduced dysmenorrhea and nonmenstrual pelvic pain (NMPP) in premenopausal women with endometriosis who received prior hormonal treatment, according to a post hoc analysis of two phase III trials presented at ESHRE 2023.

Relugolix combo reduces dysmenorrhea, NMPP in premenopausal women

17 Aug 2023

Linzagolix promising for endometriosis-associated pain

16 Aug 2023 by

Once-daily treatment with linzagolix, a novel, oral GnRH* antagonist, with or without add-back therapy (ABT), reduces dysmenorrhoea and nonmenstrual pelvic pain (NMPP), among women with endometriosis, according to the EDELWEISS 3 trial presented at ESHRE 2023.

Linzagolix promising for endometriosis-associated pain

16 Aug 2023

Testosterone pretreatment of no benefit to women at risk of poor response to IVF

14 Aug 2023 by

Treatment with transdermal testosterone prior to initiating ovarian stimulation for in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) does not appear to increase the chances of becoming pregnant for women at risk of having a poor ovarian response, as shown in the T-TRANSPORT trial presented at ESHRE 2023.

Testosterone pretreatment of no benefit to women at risk of poor response to IVF

14 Aug 2023

Pre-eclampsia children prone to higher BP in early life

14 Aug 2023

Children born to mothers with pre-eclampsia (PE) tend to develop adverse blood pressure (BP) profile and arterial stiffness early in life, reveals a study.

Pre-eclampsia children prone to higher BP in early life

14 Aug 2023

News & Updates

Filter by Specialty:

Specialty:

US FDA greenlights first pill for postpartum depression

US FDA greenlights first pill for postpartum depression

General anaesthesia and oxytocin significantly associated with PPH in twin pregnancies

General anaesthesia and oxytocin significantly associated with PPH in twin pregnancies

Niraparib maintenance prolongs PFS in advanced ovarian cancer

Niraparib maintenance prolongs PFS in advanced ovarian cancer

Magnesium sulfate for women at risk of preterm birth does not reduce cerebral palsy risk

Magnesium sulfate for women at risk of preterm birth does not reduce cerebral palsy risk

OGTT-based model predicts GDM in pregnant women

OGTT-based model predicts GDM in pregnant women

Oral contraceptive use not linked to CVD, all-cause death in women

Oral contraceptive use not linked to CVD, all-cause death in women

Relugolix combo reduces dysmenorrhea, NMPP in premenopausal women

Relugolix combo reduces dysmenorrhea, NMPP in premenopausal women

Linzagolix promising for endometriosis-associated pain

Linzagolix promising for endometriosis-associated pain

Testosterone pretreatment of no benefit to women at risk of poor response to IVF

Testosterone pretreatment of no benefit to women at risk of poor response to IVF

Pre-eclampsia children prone to higher BP in early life

Pre-eclampsia children prone to higher BP in early life